GRAL Stock Analysis: GRAIL | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 2.966m USD | 12M Return: 65.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 37.0M
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GRAIL, Inc. (NASDAQ: GRAL) is a commercial-stage healthcare company that markets multi-cancer early detection (MCED) tests and related services in the United States and select international markets. Its lead product, Galleri, is a blood-based screening test intended for asymptomatic adults aged 50 and older, and the company also provides a diagnostic aid designed to help clinicians accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Beyond screening, GRAIL offers development services such as support for clinical studies, pilot testing, research collaborations, and therapy development partnerships with biopharmaceutical companies. The company is also building a precision oncology franchise built around a research-use-only (RUO) targeted methylation-based platform, with applications spanning disease prognostication, risk stratification, minimal residual disease (MRD) detection, and recurrence/relapse monitoring.
GRAIL sits within the biotechnology sub-industry of healthcare, a segment in which methylation-based liquid biopsy has become a leading technology for non-invasive cancer detection and disease monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California, and completed its public listing on NASDAQ in June 2024.
- Galleri test revenue growth accelerates US and international adoption
- FDA approval pathway for Galleri multi-cancer screening test advances
- NHS-Galleri trial results support reimbursement coverage decisions
| Net Income: -395.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 6.03 > 1.0 |
| NWC/Revenue: 514.1% < 20% (prev 499.3%; Δ 14.79% < -1%) |
| CFO/TA -0.10 > 3% & CFO -291.0m > Net Income -395.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.6m) vs 12m ago 18.46% < -2% |
| Gross Margin: -14.80% > 18% (prev -58.18%; Δ 43.38% > 0.5%) |
| Asset Turnover: 5.53% > 50% (prev 4.59%; Δ 0.94% > 0%) |
| Interest Coverage Ratio: -22.43 > 6 (EBIT TTM -493.6m / Interest Expense TTM 22.0m) |
| A: 0.29 (Total Current Assets 877.3m - Total Current Liabilities 74.7m) / Total Assets 2.80b |
| B: -3.68 (Retained Earnings -10.3b / Total Assets 2.80b) |
| C: -0.17 (EBIT TTM -493.6m / Avg Total Assets 2.83b) |
| D: 8.26 (Book Value of Equity 2.50b / Total Liabilities 302.8m) |
| Altman-Z'' = -2.61 = D |
| DSRI: 0.88 (Receivables 20.3m/19.4m, Revenue 156.1m/130.7m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.93 (AQ_t 0.65 / AQ_t-1 0.70) |
| SGI: 1.19 (Revenue 156.1m / 130.7m) |
| TATA: -0.04 (NI -395.3m - CFO -291.0m) / TA 2.80b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 72.00 with a total of 509,296 shares traded. Over the past week, the price has changed by +4.18%, over one month by +22.89%, over three months by +57.79% and over the past year by +65.94%.
Current recommended Stop Loss: 67.00 (which is 6.9% or 1.2 ATR below the current price).
GRAIL has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold GRAL.
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 66 | -8.3% |
P/S = 18.998
P/B = 1.1689
Revenue TTM = 156.1m USD
EBIT TTM = -493.6m USD
EBITDA TTM = -337.8m USD
Long Term Debt = 41.1m USD (estimated: total debt 51.0m - short term 9.94m)
Short Term Debt = 9.94m USD (from shortTermDebt, last quarter)
Debt = 51.0m USD (from shortLongTermDebtTotal, last quarter) (leases 51.0m already included)
Net Debt = -772.1m USD (calculated: Debt 51.0m - CCE 823.1m)
Enterprise Value = 2.19b USD (2.97b + Debt 51.0m - CCE 823.1m)
Interest Coverage Ratio = -22.43 (Ebit TTM -493.6m / Interest Expense TTM 22.0m)
EV/FCF = -7.53x (Enterprise Value 2.19b / FCF TTM -291.4m)
FCF Yield = -13.28% (FCF TTM -291.4m / Enterprise Value 2.19b)
FCF Margin = -186.7% (FCF TTM -291.4m / Revenue TTM 156.1m)
Net Margin = -253.2% (Net Income TTM -395.3m / Revenue TTM 156.1m)
Gross Margin = -14.80% ((Revenue TTM 156.1m - Cost of Revenue TTM 179.2m) / Revenue TTM)
Gross Margin QoQ = 47.91% (prev -25.54%)
Tobins Q-Ratio = 0.78 (Enterprise Value 2.19b / Total Assets 2.80b)
Interest Expense / Debt = 43.12% (Interest Expense 22.0m / Debt 51.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -390.0m (EBIT -493.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.74 (Total Current Assets 877.3m / Total Current Liabilities 74.7m)
Debt / Equity = 0.02 (Debt 51.0m / totalStockholderEquity, last quarter 2.50b)
Debt / EBITDA = 2.29 (negative EBITDA) (Net Debt -772.1m / EBITDA -337.8m)
Debt / FCF = 2.65 (negative FCF - burning cash) (Net Debt -772.1m / FCF TTM -291.4m)
Total Stockholder Equity = 2.41b (last 4 quarters mean from totalStockholderEquity)
RoA = -13.99% (Net Income -395.3m / Total Assets 2.80b)
RoE = -16.42% (Net Income TTM -395.3m / Total Stockholder Equity 2.41b)
RoCE = -20.15% (EBIT -493.6m / Capital Employed (Equity 2.41b + L.T.Debt 41.1m))
RoIC = -14.28% (negative operating profit) (NOPAT -390.0m / Invested Capital 2.73b)
WACC = 12.16% (E(2.97b)/V(3.02b) * Re(11.78%) + D(51.0m)/V(3.02b) * Rd(43.12%) * (1-Tc(0.21)))
Discount Rate = 11.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.28 | Cagr: 13.23%
[DCF] Fair Price = unknown (Cash Flow -291.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.54 | # QB: 0
Revenue Correlation: 98.46 | Revenue CAGR: 25.73% | SUE: 0.44 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-2.41 | Chg30d=+16.87% | Revisions=-25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-2.37 | Chg30d=+17.31% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=-9.12 | Chg30d=+15.59% | Revisions=-25% | GrowthEPS=+22.0% | GrowthRev=+21.7%
EPS next Year (2027-12-31): EPS=-9.72 | Chg30d=-2.61% | Revisions=-25% | GrowthEPS=-6.6% | GrowthRev=+24.9%
[Analyst] Revisions Ratio: -57% (up=0, down=4)